Daclizumab with Greek suufix
( DrugBank: Daclizumab / KEGG DRUG: Daclizumab )
1 disease
告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
13 | 多発性硬化症/視神経脊髄炎 | 4 |
13. 多発性硬化症/視神経脊髄炎
臨床試験数 : 3,340 / 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238
Showing 1 to 4 of 4 trials
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | EUCTR2008-005559-46-DE (EUCTR) | 08/12/200920091208 | 26/06/200920090626 | An Extension Study to Evaluate the Safety and Efficacy of DAC HYP in Subjects with Multiple Sclerosis who have completed Treatment in the study 205MS201 (SELECT) An Extension Study to Evaluate the Safety and Efficacy of DAC HYP in Subjects with Multiple Sclerosi ... | A Double-Blind, Multicenter, Extension Study to Evaluate the Safety and Efficacy of DAC HYP in Subjects with Multiple Sclerosis Who Have Completed Treatment in Study 205MS201 (SELECT) - SELECTION A Double-Blind, Multicenter, Extension Study to Evaluate the Safety and Efficacy of DAC HYP in Subje ... | Relapsing-remitting Multiple Sclerosis MedDRA version: 14.1;Level: PT;Classification code 10063399;Term: Relapsing-remitting multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] Relapsing-remitting Multiple Sclerosis MedDRA version: 14.1;Level: PT;Classification code 10063399;T ... | Product Name: DACLIZUMAB HYP Product Code: BIIB019 INN or Proposed INN: Daclizumab with Greek suufix Other descriptive name: Daclizumab HYP (DAC HYP) Product Name: DACLIZUMAB HYP Product Code: BIIB019 INN or Proposed INN: Daclizumab with Greek suufix Other descriptive name: Daclizumab HYP (DAC HYP) Product Name: DACLIZUMAB HYP Product Code: BIIB019 INN or Proposed INN: Daclizumab with Greek suufix Ot ... | Biogen Idec Ltd. | NULL | Not Recruiting | Female: yes Male: yes | 600 | Hungary;Czech Republic;Poland;Ukraine;Russian Federation;Germany;United Kingdom;India | |||
2 | EUCTR2008-005559-46-HU (EUCTR) | 04/08/200920090804 | 05/06/200920090605 | A Double-Blind, Multicenter, Extension Study to Evaluate the Safety and Efficacy of DAC HYP in Subjects with Multiple Sclerosis Who Have Completed Treatment in Study 205MS201 (SELECT) - SELECTION A Double-Blind, Multicenter, Extension Study to Evaluate the Safety and Efficacy of DAC HYP in Subje ... | A Double-Blind, Multicenter, Extension Study to Evaluate the Safety and Efficacy of DAC HYP in Subjects with Multiple Sclerosis Who Have Completed Treatment in Study 205MS201 (SELECT) - SELECTION A Double-Blind, Multicenter, Extension Study to Evaluate the Safety and Efficacy of DAC HYP in Subje ... | Relapsing-remitting Multiple Sclerosis/1 MedDRA version: 14.1;Level: PT;Classification code 10063399;Term: Relapsing-remitting multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] Relapsing-remitting Multiple Sclerosis/1 MedDRA version: 14.1;Level: PT;Classification code 10063399 ... | Product Name: DACLIZUMAB HYP Product Code: BIIB019 INN or Proposed INN: Daclizumab with Greek suufix Other descriptive name: Daclizumab HYP (DAC HYP) Product Name: DACLIZUMAB HYP Product Code: BIIB019 INN or Proposed INN: Daclizumab with Greek suufix Other descriptive name: Daclizumab HYP (DAC HYP) Product Name: DACLIZUMAB HYP Product Code: BIIB019 INN or Proposed INN: Daclizumab with Greek suufix Ot ... | Biogen Idec Ltd. | NULL | Not Recruiting | Female: yes Male: yes | 600 | Czech Republic;Hungary;Poland;Ukraine;Russian Federation;Germany;United Kingdom;India | |||
3 | EUCTR2008-005559-46-GB (EUCTR) | 18/05/200920090518 | 27/07/201020100727 | An Extension Study to Evaluate the Safety and Efficacy of DAC HYP in Subjects with Multiple Sclerosis who have completed Treatment in the study 205MS201 (SELECT) An Extension Study to Evaluate the Safety and Efficacy of DAC HYP in Subjects with Multiple Sclerosi ... | A Double-Blind, Multicenter, Extension Study to Evaluate the Safety and Efficacy of DAC HYP in Subjects with Multiple Sclerosis Who Have Completed Treatment in Study 205MS201 (SELECT) - SELECTION A Double-Blind, Multicenter, Extension Study to Evaluate the Safety and Efficacy of DAC HYP in Subje ... | Relapsing-remitting Multiple Sclerosis MedDRA version: 14.1;Level: PT;Classification code 10063399;Term: Relapsing-remitting multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] Relapsing-remitting Multiple Sclerosis MedDRA version: 14.1;Level: PT;Classification code 10063399;T ... | Product Name: DACLIZUMAB HYP Product Code: BIIB019 INN or Proposed INN: Daclizumab with Greek suufix Other descriptive name: Daclizumab HYP (DAC HYP) Product Name: DACLIZUMAB HYP Product Code: BIIB019 INN or Proposed INN: Daclizumab with Greek suufix Other descriptive name: Daclizumab HYP (DAC HYP) Product Name: DACLIZUMAB HYP Product Code: BIIB019 INN or Proposed INN: Daclizumab with Greek suufix Ot ... | Biogen Idec Ltd. | NULL | Not Recruiting | Female: yes Male: yes | 600 | Phase 2 | Hungary;Czech Republic;Poland;Ukraine;Russian Federation;Germany;United Kingdom;India | ||
4 | EUCTR2008-005559-46-CZ (EUCTR) | 23/01/200920090123 | 28/11/200820081128 | An Extension Study to Evaluate the Safety and Efficacy of DAC HYP in Subjects with Multiple Sclerosis who have completed Treatment in the study 205MS201 (SELECT) An Extension Study to Evaluate the Safety and Efficacy of DAC HYP in Subjects with Multiple Sclerosi ... | A Double-Blind, Multicenter, Extension Study to Evaluate the Safety and Efficacy of DAC HYP in Subjects with Multiple Sclerosis Who Have Completed Treatment in Study 205MS201 (SELECT) - SELECTION A Double-Blind, Multicenter, Extension Study to Evaluate the Safety and Efficacy of DAC HYP in Subje ... | Relapsing-remitting Multiple Sclerosis MedDRA version: 14.0;Level: PT;Classification code 10063399;Term: Relapsing-remitting multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] Relapsing-remitting Multiple Sclerosis MedDRA version: 14.0;Level: PT;Classification code 10063399;T ... | Product Name: DACLIZUMAB HYP Product Code: BIIB019 INN or Proposed INN: Daclizumab with Greek suufix Other descriptive name: Daclizumab HYP (DAC HYP) Product Name: DACLIZUMAB HYP Product Code: BIIB019 INN or Proposed INN: Daclizumab with Greek suufix Other descriptive name: Daclizumab HYP (DAC HYP) Product Name: DACLIZUMAB HYP Product Code: BIIB019 INN or Proposed INN: Daclizumab with Greek suufix Ot ... | Biogen Idec Ltd. | NULL | Not Recruiting | Female: yes Male: yes | 600 | Hungary;Czech Republic;Poland;Ukraine;Russian Federation;Germany;United Kingdom;India |